Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, Republic of Korea.
Jpn J Clin Oncol. 2012 Oct;42(10):948-54. doi: 10.1093/jjco/hys114. Epub 2012 Jul 17.
The present study was performed to assess the usefulness of involved-field irradiation and the impact of (18)F-fluorodeoxyglucose-positron emission tomography-based staging on treatment outcomes in limited-stage small cell lung cancer.
Eighty patients who received definitive chemoradiotherapy for limited-stage small cell lung cancer were retrospectively analyzed. Fifty patients were treated with involved-field irradiation, which means that the radiotherapy portal includes only clinically identifiable tumors. The other 30 patients were irradiated with a comprehensive portal, including uninvolved mediastinal and/or supraclavicular lymph nodes, so-called elective nodal irradiation. No significant difference was seen in clinical factors between the two groups.
At a median follow-up of 27 months (range, 5-75 months), no significant differences were observed in 3 year overall survival (44.6 vs. 54.1%, P= 0.220) and 3 year progression-free survival (24.4 vs. 42.8%, P= 0.133) between the involved-field irradiation group and the elective nodal irradiation group, respectively. For patients who did not undergo positron emission tomography scans, 3 year overall survival (29.3 vs. 56.3%, P= 0.022) and 3 year progression-free survival (11.0 vs. 50.0%, P= 0.040) were significantly longer in the elective nodal irradiation group. Crude incidences of isolated nodal failure were 6.0% in the involved-field irradiation group and 0% in the elective nodal irradiation group, respectively. All isolated nodal failures were developed in patients who had not undergone positron emission tomography scans in their initial work-ups.
If patients did not undergo positron emission tomography-based staging, the omission of elective nodal irradiation resulted in impaired survival outcomes and raised the risk of isolated nodal failure. Therefore, involved-field irradiation for limited-stage small cell lung cancer might be reasonable only with positron emission tomography scan implementation.
本研究旨在评估局限期小细胞肺癌采用累及野照射(IFRT)的效用,以及基于 18F-氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)的分期对治疗结果的影响。
回顾性分析了 80 例接受局限期小细胞肺癌根治性放化疗的患者。50 例患者接受累及野照射(IFRT)治疗,即放射治疗野仅包括临床可识别的肿瘤。另外 30 例患者接受全野照射(ENI),包括未累及的纵隔和/或锁骨上淋巴结,即所谓的选择性淋巴结照射(ENI)。两组患者的临床因素无显著差异。
中位随访时间为 27 个月(范围为 5-75 个月),在 IFRT 组和 ENI 组中,3 年总生存率(44.6%比 54.1%,P=0.220)和 3 年无进展生存率(24.4%比 42.8%,P=0.133)均无显著差异。对于未行 PET 扫描的患者,ENI 组的 3 年总生存率(29.3%比 56.3%,P=0.022)和 3 年无进展生存率(11.0%比 50.0%,P=0.040)显著延长。在 IFRT 组和 ENI 组中,单纯淋巴结失败的粗发生率分别为 6.0%和 0%。所有单纯淋巴结失败均发生在初始检查未行 PET 扫描的患者中。
如果患者未行 PET 分期,省略选择性淋巴结照射会导致生存结局受损,并增加单纯淋巴结失败的风险。因此,只有在实施 PET 扫描的情况下,局限期小细胞肺癌的 IFRT 可能才是合理的。